Syndax Pharmaceuticals stock: event driven snapshot

Syndax Pharmaceuticals (SNDX) has been drawing investor attention after recent trading performance, with the stock down 16% over the past month and 21% over the past 3 months from a last close of US$17.34.

The recent weakness, including a 3.77% 1 day and 11.49% 7 day share price decline, has pulled year to date share price returns to a fall of 18.59%. However, the 1 year total shareholder return of 51.44% still reflects earlier strength.

If you are weighing up Syndax alongside other cancer and biotech opportunities, this is a useful moment to scan a broader pool of healthcare AI focused stocks via 39 healthcare AI stocks

With revenue of US$217.17 million, a net loss of US$243.25 million, a market cap around US$1.60b, and a quoted intrinsic discount, you have to ask: is SNDX undervalued or already pricing in future growth?

Most Popular Narrative: 56.1% Undervalued

Analysts following Syndax see a fair value of $39.50 per share, well above the last close at $17.34, and link that gap to aggressive long term growth assumptions.

Late-stage pipeline advancements (including frontline trials, lifecycle management, and expansion into new indications like IPF for Niktimvo), coupled with strong clinical data and market-leading positions in precision oncology, provide robust long-term growth avenues aligned with surging demand for targeted therapies, supporting sustained multi-year earnings momentum.

Curious what kind of revenue ramp, margin lift, and future earnings multiple are baked into that $39.50 figure? The narrative leans on bold growth forecasts, rising profitability, and a premium valuation hurdle that goes well beyond the broader biotech sector.

Result: Fair Value of $39.50 (UNDERVALUED)

However, this depends heavily on just two late-stage drugs. Any clinical or regulatory setback, or slower-than-expected commercial uptake, could quickly challenge that potential upside.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

With sentiment this mixed, it makes sense to look at the numbers yourself and decide how much optimism you are comfortable with. To see what investors are currently excited about, check the 2 key rewards

Looking for more investment ideas?

If SNDX has your attention, do not stop here. Use this moment to refresh your watchlist with fresh, data driven stock ideas that others might miss.

• Scan for value by checking out companies that screen as mispriced relative to their fundamentals through the 49 high quality undervalued stocks.
• Prioritize resilience by focusing on businesses with stronger balance sheets and healthier fundamentals using the solid balance sheet and fundamentals stocks screener (46 results).
• Get ahead of the crowd by reviewing a screener containing 22 high quality undiscovered gems before they land on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.